PHARMACY

FDA approves Alimta as maintenance therapy for advanced lung cancer

BY Alaric DeArment

ROCKVILLE, Md. The Food and Drug Administration has approved the first maintenance therapy for advanced lung cancer, the agency announced Monday.

The agency announced the approval of Eli Lilly & Co.’s Alimta (pemetrexed), an injected drug that works by disrupting the B-vitamin folate, which is needed for cell replication in patients with non-small cell lung cancer.

“This drug represents a new approach in the treatment of advanced non-small cell lung cancer,” said Richard Pazdur, director of the FDA’s Office of Oncology Products, in the Center for Drug Evaluation and Research. “Typically, patients whose tumors respond to chemotherapy do not receive further treatment after four-to-six chemotherapy cycles.”

Maintenance therapies are designed to prevent tumors from returning after they have been shrunk through chemotherapy.

The FDA originally approved the drug in 2004 as a treatment for the cancer mesothelioma.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Biogen Idec, Acorda Therapeutics to develop, commercialize MS drug

BY Alaric DeArment

CAMBRIDGE, Mass. Two drug makers have announced plans to develop and commercialize a multiple sclerosis treatment in markets outside the United States.

Biogen Idec and Acorda Therapeutics said the agreement to market Fampridine-SR (4-aminopyridine) was a sublicensing of an existing license agreement between Acorda and a subsidiary of Elan Corp. The drug is an orally administered, sustained-release drug being developed to improve walking ability in patients with MS.

Under the terms of the agreement, Biogen Idec will commercialize Fampridine-SR and other aminopyridine products in markets outside the United States, and also will have responsibility for regulatory affairs and future clinical development of the drug. In exchange, Acorda will receive an upfront payment of $110 million and additional payments of up to $400 million based on the successful achievement of future regulatory and sales milestones.

The companies said the Food and Drug Administration is reviewing a regulatory approval application for the drug for the U.S. market.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Study: Joint replacement patients with diabetes greatly benefit from controlled glucose

BY Alaric DeArment

ROSEMONT, Ill. The risk of complications that diabetes patients often have when undergoing total joint replacement decreases when they have their glucose levels under control, according to a recent study.

Published in the July issue of The Journal of Bone and Joint Surgery, the study found that diabetics with uncontrolled glucose levels are more than three times as likely as those with their levels under control to experience a stroke or death after joint replacement surgery, and are approximately twice as likely to experience post-operative bleeding and infection.

“We found that controlled glucose levels really do make a difference for the patient,” Duke University Medical Center orthopedic surgeon and study co-author Milford Marchant said. “It did not matter if the patient had Type 1 or Type 2 diabetes.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?